 |
Molika Ashford is a GenomeWeb contributing editor and covers personalized medicine and molecular diagnostics. E-mail Molika Ashford. |
Canada's PROOF Center to Develop Risk Stratification Test to Personalize COPD Treatment
April 25, 2012
Canada's PROOF Center to Develop Risk Stratification Test to Personalize COPD Treatment
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- HTG to Commercialize PROOF's COPD Risk Stratification Test; Aims for Launch Next Year
December 5, 2012 / Pharmacogenomics Reporter - GSK to Buy Cellzome for $99M as Pharma Interest in Chemical Proteomics Continues to Build
May 18, 2012 / ProteoMonitor - With Celgene Partnership Epizyme Hopes to Accelerate Personalized Epigenetic Drug Development
May 16, 2012 / Pharmacogenomics Reporter - UNC Team Takes Proteomic Approach to Study Drug Resistance in Triple-Negative Breast Cancer
April 20, 2012 / ProteoMonitor - Biodesix Inks Deal to Test Veristrat in Phase III Clinical Trial for Kadmon Lung Cancer Drug
March 2, 2012 / ProteoMonitor